Buy Lupkynis (voclosporin) Online

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs, including the kidneys. Lupus nephritis (LN) is a serious complication of SLE that causes inflammation and damage to the kidneys, which can progress to end-stage renal disease and other complications. Treatment for LN typically involves immunosuppressive therapies to reduce inflammation and prevent further damage to the kidneys.

Lupkynis (voclosporin) is a medication that is used in combination with other immunosuppressive agents to treat adults with active LN. It is a calcineurin inhibitor that works by blocking the activity of T-lymphocytes and other immune cells that contribute to inflammation in the kidneys. Voclosporin was designed to be more potent and selective than other calcineurin inhibitors, such as cyclosporine A, with a lower risk of toxicity and drug interactions.

Clinical trials have demonstrated the efficacy of voclosporin in inducing and maintaining remission in patients with active LN. In the AURA-LV trial, which enrolled patients with LN who had not received prior immunosuppressive therapy, 40.8% of patients who received voclosporin in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids achieved complete remission, compared to 22.5% of patients who received placebo plus MMF and corticosteroids. Voclosporin was also associated with a significantly lower risk of treatment failure or worsening of disease.

In the AURORA 1 trial, which enrolled patients with active LN despite prior immunosuppressive therapy, 41.2% of patients who received voclosporin in combination with MMF and low-dose corticosteroids achieved complete remission, compared to 23.3% of patients who received placebo plus MMF and corticosteroids. Voclosporin was also associated with a lower risk of treatment failure or worsening of disease and a lower prednisone dose.

The most common adverse events associated with voclosporin in clinical trials were gastrointestinal symptoms, such as nausea and diarrhea, and infections. Hypertension and mild renal impairment were also reported. However, voclosporin was associated with a lower risk of nephrotoxicity and drug interactions compared to cyclosporine A.

In summary, Lupkynis (voclosporin) is a new medication that has demonstrated efficacy in treating adults with active LN in combination with other immunosuppressive agents. The drug has shown a higher rate of complete remission and a lower rate of treatment failure or worsening of disease compared to standard therapy. Given the role of LN in the progression of SLE and the significant morbidity and mortality associated with end-stage renal disease, voclosporin represents an important advance in the treatment of LN and a promising addition to the arsenal of therapies for SLE. However, further research is necessary to determine the long-term safety and efficacy of voclosporin and its optimal use in combination with other agents.